## SUPPLEMENTAL MATERIAL

Nussbaum et al., https://doi.org/10.1084/jem.20162031

JEM S19




Figure S1.  $Rorc^{fm+}$  ILCs from various organs possess different expression pattern. (A) Frequencies of  $Rorc^{fm+}$  ILCs within the CD45 compartment of various organs of  $Rorc^{fm-}$  Rag 1<sup>-/-</sup> mice. Graphs represent pooled data from two independent experiments,  $n \ge 4$  each (means  $\pm$  SEM). (B) Frequencies of  $Rorc^{fm-}$  ILCs of within the CD45 compartment of various organs of  $Rorc^{fm-}$  (WT) mice. Graphs represent pooled data from two independent experiments,  $n \ge 4$  each (means  $\pm$  SEM). (C) Histograms of lymphoid (dark) splenic (spl), LN, thymic, and nonlymphoid (light) siLP, liver, or lung  $Rorc^{fm+}$  ILCs. Representative histograms of two independent experiments,  $n \ge 5$  each. (D) Dimensionality reduction using t-SNE. Data from  $Rorc^{fm+}$  ILCs of spleen and siLP (of  $Rorc^{fm-}$  [WT]) mice; gated on live, single lin-CD45<sup>+</sup> $Rorc^{fm+}$  ILCs, which were transformed and plotted in two t-SNE dimensions using R software. Clustering was performed using the flowSOM algorithm (k = 5). Depicted are the combined spleen and siLP data sets (left), the siLP dataset only (middle), and spleen dataset only (right). (E) ILC3- and NK cell-associated markers plotted in a heat map across flowSOM clusters from D. (F) Expression pattern of ILC3- and NK cell-associated markers depicted in the two t-SNE dimensions.




Figure S2. Lymphoid  $Rorc^{fm+}$  ILCs suppress tumor growth, whereas nonlymphoid  $Rorc^{fm+}$  ILCs fail to do so.  $II12rb2^{-f-}$  mice were s.c. challenged with B16–IL-12 coinjected with splenic (spl)-, LN-, siLP-, or liver-derived  $Rorc^{fm+}$  ILCs or no ILCs. (A) Tumor growth of B16–IL-12 tumor cells coinjected with splenic (spl)  $Rorc^{fm+}$  ILCs (open circles), siLP-derived  $Rorc^{fm+}$  ILCs (dark gray squares), LN-derived  $Rorc^{fm+}$  ILCs (gray open squares), hepatic (liver)  $Rorc^{fm+}$  ILCs (light gray squares), or the absence of ILCs (closed circles) over time. For comparison of the tumor growth curve two-way ANOVA with Tukey's multiple comparisons test was used. \*\*\*\*, P < 0.001. (B) Quantification of tumor burden 24 d after tumor inoculation. Graph represents pooled data from three independent experiments,  $n \ge 5$  each (means  $\pm$  SEM). One-way ANOVA with Tukey's multiple comparisons test was performed. \*, P < 0.05; \*\*\*, P < 0.01; \*\*\*\*, P < 0.001.




Figure S3. Rorc-fate map crossed to Eomes-reporter mice allow identification of type 1 and type 3 ILC subsets. (A) Schematic representation of the  $Rorc^{cre}$  mice crossed to the  $Eomes^{GFP}$ -Rosa26Re<sup>YFP/+</sup> mice, labeling all cells expressing RORyt with YFP and all cells expressing Eomes with GFP. (B) Gating strategy to identify ILC3s derived from the Rorc lineage ( $Rorc^{fm+}$  ILCs), Eomes-expressing NK cells, and Eomes-ILC1s in the spleen (spl). For exclusion of the adaptive immune cells and myeloid cells lin $^-$  (CD3 $^-$ CD5 $^-$ CD11c $^-$ CD19 $^-$ GR-1 $^-$ ), live, single CD45 $^+$  cells were gated. ILC1s, NK cells, and NCR $^+$  ILC3s were identified within the NCR $^+$  (NK1.1 $^+$ NKp46 $^+$ ) cell population, whereas NCR $^-$  ILC3s were identified in the NCR $^-$  population. NCR $^+$  and NCR $^-$ ILC3 are summarized as Eometa-ILC3.

JEM S21




Figure S4. **NGS reveals differentially expressed genes by splenic** *Rorc*<sup>fm+</sup> **ILCs compared with other ILC subsets.** (A and B) Pairwise comparison of the four experimental groups depicted in a Venn diagram. 78 genes are significantly down-regulated, and 208 are up-regulated when comparing all conditions (*Eomes*<sup>+</sup> NK cells, *Eomes*<sup>-</sup> ILC1s, and siLP *Rorc*<sup>fm+</sup> ILCs) to splenic (spl) *Rorc*<sup>fm+</sup> ILCs (altered to a minimum significance threshold of P < 0.01 and fold change >1 or -1). (C) Top 30 list of genes down-regulated by splenic (spl) *Rorc*<sup>fm+</sup> ILCs compared with *Eomes*<sup>+</sup> NK cells, *Eomes*<sup>-</sup> ILC1s, and siLP *Rorc*<sup>fm+</sup> ILCs. (D) Top 30 list of genes up-regulated by splenic (spl) *Rorc*<sup>fm+</sup> ILCs compared with *Eomes*<sup>+</sup> NK cells, *Eomes*<sup>-</sup> ILC1s, and siLP *Rorc*<sup>fm+</sup> ILCs. (E) Heat maps of differentially expressed genes clustered to the indicated category. Heat maps show representative data of one sample per group.




Figure S5. **Splenic** *Rorc*<sup>fm+</sup> **ILCs** only express low amounts of cytotoxic molecules and an activated phenotype. (A) Expression pattern of cytotoxic molecules by the different splenic and siLP  $Rorc^{fm+}$  ILC data from NGS (means  $\pm$  SD; Fig. 6). (B) Expression pattern of activation markers by the different splenic and siLP  $Rorc^{fm+}$  ILCs; data from NGS (means  $\pm$  SD; Fig. 6).

JEM S23